The functions of IL-2 therapy are known to directly activate CTLs in lymphoid and nonlymphoid tissues17,25, but it is not yet clear whether the preexisting T cells inside the tumor are sufficient for the effectiveness of IL-2 therapy. This evidence concerns the gene IL2 and neoplasm.